A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2020
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary) ; Chlorambucil; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 27 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2018 Planned End Date changed from 1 Apr 2024 to 30 Apr 2024.
- 02 May 2018 Status changed from not yet recruiting to recruiting.